April 29, 2014 10:10 AM

Pozen shares fall after FDA finds problems with new drug application

Pozen shares fell more than 10 percent Monday after the Chapel Hill company announced that federal regulators have informed the company that its new drug application cannot be approved in its current form.

Related content